ArticleMolecular genetics and genomics : MGG2026
Neurexophilin 4 facilitates the malignant progression of kidney renal clear cell carcinoma by regulating PI3K/AKT-mediated glycolysis.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is a major subtype of renal cell carcinoma and characterized by metabolic reprogramming, especially glycolysis. Neurexophilin 4 (NXPH4) is associated with malignancy of several cancers. However, its function in ccRCC remains unclear. In the current study, several online bioinformatics databases confirmed that NXPH4 was highly expressed in ccRCC tissues and was correlated with poor prognosis in patients with ccRCC. Notably, inhibition of NXPH4 suppressed cell viability, invasion and migration of ccRCC cells, and promoted cell apoptosis; while its overexpression produced the opposite effects. Further online database revealed a positive correlation between NXPH4 expression and glycolysis-related genes LDHA and HK2 in ccRCC tissues. Suppression of NXPH4 obviously decreased protein expression of LDHA and HK2 in ccRCC cells. Importantly, knockdown of NXPH4 attenuated glycolysis by inhibiting glucose uptake, lactate, ATP levels, extracellular acidification rate (ECAR) and increasing oxygen consumption rate (OCR); however, NXPH4 up-regulation promoted glycolysis. Intriguingly, the pro-tumor effects of NXPH4 were reversed by the glycolysis antagonist 2-DG. Additionally, NXPH4 elevation activated the PI3K/AKT pathway, while blocking this pathway significantly offset NXPH4-driven glycolysis, viability, invasion and migration. Collectively, NXPH4 may contribute to cancer cell growth and metastatic potential in ccRCC by activating the PI3K/AKT-evoked glycolysis, supporting it as a promising therapeutic target for ccRCC.
Indexed as
Identifiers
42762350What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.